Vigliptin Duo Tablet 50/1000 Milligrams
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
MFDS item code 201507539 · Approved 2015.11.03
This product's status changed to Approval withdrawn on 2024.10.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used along with dietary and exercise therapies to help control blood sugar levels in patients with type 2 diabetes. It is effective for patients starting drug therapy for the first time or those who find it difficult to control blood sugar with monotherapy. It is also used when blood sugar control is insufficient with sitagliptin or metformin monotherapy, or as an alternative when both drugs are used together. In cases where blood sugar control is difficult, it can be more effective when combined with sulfonylureas, thiazolidinediones, or insulin. This medication improves blood sugar control in type 2 diabetes when used with various treatment methods.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used for the treatment of diabetes and can potentially cause severe allergic reactions. If symptoms such as skin rash, breathing difficulties, or swelling of the face or neck occur after taking this medication, you should immediately stop taking it and seek medical attention. This drug may cause a condition known as pancreatitis, which is an inflammation of the pancreas, so if severe abdominal pain, vomiting, or nausea occurs while taking it, you should go to the hospital immediately. Patients with poor kidney function, serious infections, or heart failure are at risk when taking this medication, and it is essential to consult a physician. Additionally, if you are scheduled for a test that uses iodine contrast media, you should discontinue this medication for a certain period before and after the test and ensure that kidney function is normal. Pregnant women or women who may become pregnant, as well as breastfeeding women, should avoid taking this medication. This medication can cause hypoglycemia (a condition where blood sugar drops too low), so careful monitoring of blood sugar changes is important, especially when combined with other hypoglycemic agents. While taking this medication, it is recommended to maintain regular meals and appropriate exercise, and to avoid sudden meal skipping or intense exercise. If you have liver or kidney issues, or are dehydrated, or have severe diarrhea or vomiting, you should stop taking this medication and consult a doctor. Alcohol consumption may increase risks when taken with this medication, so excessive drinking should be avoided. It is important to have regular blood tests and kidney function tests during treatment to check for any irregularities. In case of overdose, you should immediately visit a healthcare facility for appropriate treatment, as this medication can be partially removed via hemodialysis. Finally, if severe joint pain or skin blisters occur while taking this medication, you should inform your doctor immediately.
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering, and the storage temperature should be maintained between 1 and 30 degrees Celsius. This will help preserve the drug's effectiveness and prevent degradation.
Dark red oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.